First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients.
Jee-Fu HuangChia-Yen DaiChung-Feng HuangPei-Chien TsaiMing-Lun YehPo-Yau HsuShiu-Feng HuangMing-Jong BairNai-Jen HouChing-I HuangPo-Cheng LiangYi-Hung LinChih-Wen WangMing-Yen HsiehShinn-Chern ChenZu-Yau LinMing-Lung YuWan-Long ChuangPublished in: Hepatology international (2021)
A 24-week pioglitazone treatment was well-tolerated and effective in improving liver histology and reducing liver steatosis in Asian NASH patients. (ClinicalTrials.gov number: NCT01068444).